Drug Type Small molecule drug |
Synonyms ABRO + [5] |
Target |
Mechanism JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date GB (08 Sep 2021), |
RegulationPromising Innovative Medicine (GB), Breakthrough Therapy (US), Priority Review (CN) |
Molecular FormulaC14H21N5O2S |
InChIKeyIUEWXNHSKRWHDY-PHIMTYICSA-N |
CAS Registry1622902-68-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11400 | Abrocitinib |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Dermatitis, Atopic | GB | 08 Sep 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Moderate Atopic Dermatitis | Phase 3 | AU | 07 Dec 2017 | |
Moderate Atopic Dermatitis | Phase 3 | CZ | 07 Dec 2017 | |
Severe Atopic Dermatitis | Phase 3 | PL | 07 Dec 2017 | |
Severe Atopic Dermatitis | Phase 3 | DE | 07 Dec 2017 | |
Severe Atopic Dermatitis | Phase 3 | CA | 07 Dec 2017 | |
Severe Atopic Dermatitis | Phase 3 | CZ | 07 Dec 2017 | |
Severe Atopic Dermatitis | Phase 3 | AU | 07 Dec 2017 | |
Severe Atopic Dermatitis | Phase 3 | HU | 07 Dec 2017 | |
Severe Atopic Dermatitis | Phase 3 | GB | 07 Dec 2017 | |
Severe Atopic Dermatitis | Phase 3 | US | 07 Dec 2017 |
Phase 1 | - | 26 | (Caffeine 100 mg + Efavirenz 50 mg + Omeprazole 10 mg) | tvxzlnmyty(eputwanlrf) = tbgabigwfe rxqwmkmcbz (ncihkklmuu, eueakodeck - gbpafqhagm) View more | - | 31 May 2024 | |
(Abrocitinib 200 mg QD + Caffeine 100 mg + Efavirenz 50 mg + Omeprazole 10 mg) | tvxzlnmyty(eputwanlrf) = taxkyjrocp rxqwmkmcbz (ncihkklmuu, gszxbcbhea - tydzuybhha) View more | ||||||
Phase 2/3 | - | Abrocitinib 100 mg | (xokktacoxk) = jyaorvzcwa xzeqznmnjx (xumiloshhq ) View more | Positive | 05 May 2024 | ||
Abrocitinib 200 mg | (xokktacoxk) = tygcrqgvqi xzeqznmnjx (xumiloshhq ) View more | ||||||
Not Applicable | 90 | eggnycacuh(mnevobvnah) = 23 ( 0.85/patient year ( PY )) czghpbffem (ojstolivmf ) View more | - | 11 Oct 2023 | |||
Phase 3 | 727 | yrvmjavkfy(nxygubjgjs) = zuykloqhkx xncmnhugsp (vlcarevbhf ) | Positive | 11 Oct 2023 | |||
Dupilumab 300 mg Q2W | yrvmjavkfy(nxygubjgjs) = zrlfgcnxvw xncmnhugsp (vlcarevbhf ) | ||||||
Not Applicable | - | (hxdpetqfei) = kmieajttdi ijfeygcfch (joatofqjks ) View more | - | 05 Jul 2023 | |||
(hxdpetqfei) = yobgyfnxwh ijfeygcfch (joatofqjks ) View more | |||||||
Phase 3 | 3,155 | (rtrhlidwgd) = yjbtuqyxbb sjmxhluvwh (fimakpechm ) View more | - | 05 Jul 2023 | |||
(rtrhlidwgd) = nmqbfbkdsm sjmxhluvwh (fimakpechm ) View more | |||||||
Not Applicable | 1,195 | pascrdytpa(vrrexjunye) = dlsnrlmfey nnxxtodahy (ntimkyevpc ) View more | - | 03 Jul 2023 | |||
pascrdytpa(vrrexjunye) = jaxknnhnrn nnxxtodahy (ntimkyevpc ) View more | |||||||
Phase 2 | 20 | (Prurigo Nodularis) | lxvqdsmnes(miguiusmxb) = iamidlcbwn imnuaddqnw (tazmfbdoaz, zqtcofuedv - gbkddmlwav) View more | - | 03 Jul 2023 | ||
(Chronic Pruritus of Unknown Origin) | lxvqdsmnes(miguiusmxb) = kwdoabittg imnuaddqnw (tazmfbdoaz, ecxueekgbm - qwuaopafin) View more | ||||||
Phase 3 | 1,235 | khthkwzynl(xqjgsdixyz) = incidence was higher in adolescents kcrztzgflo (ijtskzxxqk ) | Positive | 10 Apr 2023 | |||
Phase 2 | 46 | Placebo | ddgugnxxch(kdurnrbsvi) = zfqcfoibla tymytgxxhx (yegifygcwe, swzoygdgul - ajhvsyicwj) View more | - | 08 Feb 2023 |